# Synplogen Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/synplogen-co

- Industry: Biotechnology
- Headquarters: Kobe-shi, Japan
- Website: www.synplogen.com
- Total disclosed funding: $13M
- Latest round: Series C (Dec 9, 2022)
- Investors on record: 4

## About

Based in Japan, Synplogen Co., Ltd. operates in the biotechnology sector, specializing in advanced DNA synthesis technologies and gene therapy solutions, aimed at supporting research and development in life sciences.Synplogen Co., Ltd. is a biotechnology company that focuses on advanced DNA synthesis technologies. Founded in 2017 and headquartered in Kobe-shi, Japan, the company has executed 4 funding deals to date. The most recent funding round was a Series C, completed on March 2, 2023, where they raised JPY 922 million from Sojitz Corporation. The total amount raised by the company stands at JPY 922 million, with a current valuation of JPY 8,679.529 million.Synplogen Co., Ltd. specializes in advanced DNA synthesis technologies, primarily focusing on the OGAB® method and the Combinatorial-OGAB™ (Combi-OGAB®) technique. These methodologies enable the precise synthesis of long-chain DNA sequences, ranging from several kilobases to over 100 kilobases, with a high success rate. The company offers services for artificial gene synthesis and DNA library construction, catering specifically to the growing gene therapy market. Their products include viral vectors for gene therapy applications, designed, developed, and analyzed through their Biofoundry™ services. Synplogen's clientele encompasses research institutions, pharmaceutical companies, and biotechnology firms globally, with a focus on markets such as North America, Europe, and Asia.In the most recent year, Synplogen reported revenue of JPY 838,523.6 in 2022. The company's revenue model is based on B2B transactions, providing specialized DNA synthesis and gene therapy products through contract-based agreements and retainer arrangements for ongoing services. The flagship products, including those generated through the unique OGAB® technology, are priced according to the complexity and scale of the projects undertaken. Collaborations with notable companies in the pharmaceutical sector enhance revenue through collective research and development initiatives.In March 2023, Synplogen Co., Ltd. raised JPY 922 million in Series C funding, aimed at strengthening its research, development, and recruitment efforts. The company plans to expand its service offerings and market presence, focusing on new products related to gene therapy and DNA synthesis technologies. Targeted markets for expansion include further penetration into North America and Europe by the end of 2024. The recent capital raise will be instrumental in supporting these initiatives and enhancing the company's technological capabilities.

## Funding rounds

- Series C, Dec 9, 2022, $4M — JAFCO Group, Mizuho Bank, KISCO, Reifycs Analytical
- Series A, May 31, 2019, $9.2M — JAFCO Group

## Investors

- JAFCO Group (https://capitalatlas.ai/funds/jafco-group) — Series A, Series C
- Mizuho Bank — Series C
- KISCO — Series C
- Reifycs Analytical — Series C